Title: A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
What is HPTN083?
HPTN083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected men and transgender women who have sex with men (MSM and TGW).
Who is participating in HPTN083 study?
HPTN083 will enroll 4,500 HIV-negative MSM and TGW, ages 18 and older at sites in the U.S., Argentina, Brazil, Peru, India, Thailand, Vietnam, and South Africa. The participants will be enrolled and followed up for up to 4.5 years.
Why is HPTN083 important?
If found to be safe and effective, the bi-monthly injectable CAB may be easier for some people to adhere to than current daily oral PrEP. The long-acting and accessible PrEP can potentially be offered as a choice of HIV prevention modalities for the most vulnerable population.
Gardasil Immunogenicity with Needle-free Injection (GINI) was a study to evaluate the safety and effectiveness of two HPV vaccine delivery regimens; by needle and syringe and needle free jet injection.
Exploration of the Neo-vagina study (EN-V) is the study to explore neovaginal and rectal HIV transmission risks and assess the feasibility of collecting biological specimens from post-operative transgender women for microbiological, immunological and
ATS is a study being done to evaluate the pattern of amphetamine-type use (ATS) by HIV status and the associated demographic and behavioral risk characteristics. The effect of ATS use on HIV and STI incidence among HIV-negative and antiretroviral adh
ANSAP is a study to determine the prevalence and incidence of anal HPV infection and high-grade anal intraepithelial neoplasia (HGAIN), and evaluate their risk factors, among HIV-positive and HIV-negative men who have sex with men (MSM) in Indonesia,